Sonoma Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Sonoma Pharmaceuticals's estimated annual revenue is currently $15M per year.
- Sonoma Pharmaceuticals's estimated revenue per employee is $428,571
- Sonoma Pharmaceuticals's total funding is $76.2M.
Employee Data
- Sonoma Pharmaceuticals has 35 Employees.
- Sonoma Pharmaceuticals grew their employee count by 3% last year.
Sonoma Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.4M | 2 | -67% | N/A | N/A |
#2 | $32M | 159 | 3% | N/A | N/A |
#3 | $35M | 121 | 3% | $62.5M | N/A |
#4 | $30.2M | 150 | 18% | N/A | N/A |
#5 | $135.9M | 676 | -1% | N/A | N/A |
#6 | $14.9M | 97 | 2% | $173M | N/A |
#7 | $110.3M | 549 | N/A | N/A | N/A |
#8 | $62.7M | 312 | -3% | N/A | N/A |
#9 | $4.9M | 49 | 32% | N/A | N/A |
#10 | $9.2M | 46 | -2% | N/A | N/A |
What Is Sonoma Pharmaceuticals?
Oculus Innovative Sciences is pioneering innovative sciences resulting in breakthrough advances in technology. Disruptive technologies that are redefining the rules of engagement in the anti-infective and wound management markets. The revolutionary Microcyn™ technology, the company’s first commercialized technology, is now available in various formulations in the United States.
keywords:N/A$76.2M
Total Funding
35
Number of Employees
$15M
Revenue (est)
3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Sonoma Pharmaceuticals News
--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn®...
Sonoma Pharmaceuticals Inc (SNOA) stock is down -48.45% over the last 12 months. InvestorsObserver's proprietary ranking system, gives SNOA...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $9M | 35 | 9% | N/A |
#2 | $5M | 35 | 0% | N/A |
#3 | $7.2M | 36 | 0% | N/A |
#4 | $7.8M | 36 | 16% | N/A |
#5 | $9.9M | 38 | 3% | N/A |